Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Limited Stage Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Li Zhang, MD) · zhangli@sysucc.org.cn

Study leads

Li Zhang, MD
Principal Investigator
Sun Yat-sen University
Yan Huang, MD
Principal Investigator
Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Beijing, China · Beijing, China

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Oakland, United States

Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

Limited Stage Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Jinan, China · Jinan, China

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Small Cell Lung Cancer · SCLC · Extensive Stage Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Indianapolis, United States · Iowa City, United States